Statement of Operations (USD $)
 3 Months Ended 9 Months Ended 150 Months Ended
Sep. 30, 2013
Sep. 30, 2012
Sep. 30, 2013
Sep. 30, 2012
Sep. 30, 2013
Revenues:          
Research $ 0 $ 0 $ 0 $ 0 $ 0
Expenses:          
General and administrative 932,762 600,242 3,001,460 2,071,008 33,061,604
Research and development 781,281 1,066,245 2,258,877 3,127,201 37,537,376
Patent fees 100,199 122,571 357,906 302,533 2,890,010
Depreciation and amortization 9,645 10,721 28,196 32,163 711,119
Total Expenses 1,823,887 1,799,779 5,646,439 5,532,905 74,200,109
Loss from Operations (1,823,887) (1,799,779) (5,646,439) (5,532,905) (74,200,109)
Other Income (Expense)          
Realized loss on marketable securities         (13,301)
Interest income 13,293 6,641 34,744 17,184 1,477,143
Interest expense         (301,147)
Other income         56,047
Unrealized (loss)/gain on fair value of warrants (217,751) (1,195,932) (1,055,505) (655,545) 3,284,476
Unrealized gain on fair value of put feature on common stock         2,315,539
Financing expense (112,559)   (112,559)   (1,084,690)
Beneficial conversion feature         (1,625,000)
Total Other Income (Expense) (317,017) (1,189,291) (1,133,320) (638,361) 4,109,067
Net Loss Before Provision for Income Taxes (2,140,904) (2,989,070) (6,779,759) (6,171,266) (70,091,042)
Provision for Income Taxes 0 0 0 0 0
Net Loss $ (2,140,904) $ (2,989,070) $ (6,779,759) $ (6,171,266) $ (70,091,042)
Net loss per share, basic and diluted $ (0.02) $ (0.03) $ (0.06) $ (0.06)  
Weighted average number of shares outstanding, basic and diluted 130,466,114 95,345,656 123,188,044 95,345,656